Mathiesen Liv, Midtvedt Tore, Solberg Claus Ola
Statens legemiddelverk, Karolinska Institutet.
Tidsskr Nor Laegeforen. 2006 Sep 21;126(18):2383-4.
Daptomycin (Cubicin) is a bactericidal lipopeptide antibiotic that was approved in February 2006 for the European market, including Norway, for the treatment of patients with complicated skin and soft tissue infections caused by Gram-positive cocci. Daptomycin is administered intravenously and eliminated mainly by the kidneys. Dose reduction is therefore necessary in patients with impaired renal function. The drug is active only against Gram-positive cocci. Daptomycin therapy of patients with complicated skin and soft tissue infections caused by Gram-positive cocci, is as effective as standard therapy with intravenous semi-synthetic penicillin or vancomycin. The agent is usually well tolerated, but side effects in skeletal muscles are more prevalent than with semi-synthetic penicillins or vancomycin. To prevent development of daptomycin resistance, the agent should be reserved for the treatment of patients with infections caused by Staphylococcus aureus that are resistant to antibiotics commonly used for the treatment of skin and soft tissue infections, e.g. penicillins or clindamycin.
达托霉素（ Cubicin）是一种杀菌性脂肽类抗生素，于2006年2月在包括挪威在内的欧洲市场获得批准，用于治疗由革兰氏阳性球菌引起的复杂性皮肤和软组织感染患者。达托霉素通过静脉给药，主要经肾脏消除。因此，肾功能受损的患者需要减少剂量。该药物仅对革兰氏阳性球菌有活性。用达托霉素治疗由革兰氏阳性球菌引起的复杂性皮肤和软组织感染患者，其疗效与静脉使用半合成青霉素或万古霉素的标准疗法相同。该药物通常耐受性良好，但与半合成青霉素或万古霉素相比，骨骼肌的副作用更为常见。为防止产生对达托霉素的耐药性，该药物应仅用于治疗对常用于治疗皮肤和软组织感染的抗生素（如青霉素或克林霉素）耐药的金黄色葡萄球菌感染患者。
